CTMX
CytomX Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Buy"
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CTMX
Cytomx Therapeutics, Inc.
A leader in the field of conditionally activated oncology therapeutics
151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080
--
CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010. The Company is a clinical-stage, oncology-focused biopharmaceutical company focused on the development of novel conditionally activated biologics designed to target the tumor microenvironment. The Company's proprietary, multifunctional, multimodal PROBODY technology platform is designed to enable the conditional activation of biotherapeutic drug candidates within tumor microcycles while minimizing drug activity in healthy tissues and circulation.
Company Financials
EPS
CTMX has released its 2024 Q4 earnings. EPS was reported at 0.22, versus the expected -0.11, beating expectations. The chart below visualizes how CTMX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CTMX has released its 2024 Q4 earnings report, with revenue of 38.09M, reflecting a YoY change of 43.17%, and net profit of 18.88M, showing a YoY change of 2155.20%. The Sankey diagram below clearly presents CTMX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
